15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Reports Promising Results With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device
26 août 2021 12h28 HE | Sorrento Therapeutics, Inc.
Sorrento’s mRNA vaccine (“STI-mRNA”) delivered with the MuVaxx™ Lymphatic Drug Delivery Device (“MuVaxx”), at 1/10th of the dose vs an LNP-mRNA reference standard1 (“LNP-mRNA”) delivered...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Announces Entry Into Option Agreement to Exclusively License MPRO Inhibitors Against SARS-CoV-2 and Variants of Concern, Including Delta, From Texas A&M University
24 août 2021 10h44 HE | Sorrento Therapeutics, Inc.
MPro is a SARS-CoV-2 enzyme that catalyzes the formation of a number of essential proteins for the viral reproduction.MPro inhibitors block this catalytic process to potentially inhibit the viral...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoid Arthritis Study Using Enbrel
23 août 2021 15h52 HE | Sorrento Therapeutics, Inc.
Rheumatoid Arthritis (RA) is one of many chronic autoimmune conditions affecting over 20 million people in the United States (NIH, 2017).Sofusa is a revolutionary technology which delivers biologic...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives
19 août 2021 09h00 HE | Sorrento Therapeutics, Inc.
PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), announced that, effective September 1, 2021, ZTlido®...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program
09 août 2021 14h39 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Promising Results in a Publication Detailing of Salicyn-30 and Other Salicylanilides in Reducing SARS-CoV‑2 Replication and Suppressing Induction of Inflammatory Cytokines in a Rodent Model
04 août 2021 12h57 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), in collaboration with The Scripps Research Institute of La Jolla, today announced that the...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
20 juil. 2021 09h00 HE | Sorrento Therapeutics, Inc.
China National Medical Product Administration (NMPA) has granted Mabpharm approval to market INFLIXIMAB biobetter in China.Sorrento holds commercialization rights outside of China and intends to meet...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
26 janv. 2021 19h09 HE | Sorrento Therapeutics, Inc.
First three patients discharged from Hospital ICU within 8 days from initial IV administration  No infusion-related adverse events noted for any patient treated to date  SAN DIEGO, Jan. 26, 2021 ...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Dr. Henry Ji to Participate in the H.C. Wainwright Bioconnect 2021 Virtual Investor Conference
10 janv. 2021 17h58 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento to Participate in the 32nd Piper Sandler Healthcare Investor Conference
29 nov. 2020 20h19 HE | Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), is pleased to announce that Dr. Henry Ji, Chairman and CEO, will be participating in the Piper...